Events
Title: KSI-501 Bispecific Anti-VEGF Anti-IL-6 Antibody Biopolymer Conjugate: First Time Results of the Multiple Ascending Dose Phase 1 Study
Presenter: Mark R. Barakat, M.D., Managing Partner and Director of Clinical Research, Retina Macula Institute of Arizona, Clinical Assistant Professor of Ophthalmology, University of Arizona College of Medicine, Phoenix, AZ
Presenter: Dr. Charles C. Wykoff, MD, PhD
Title: Tarcocimab tedromer (KSI-301) 5 mg for the treatment of wAMD: One-year primary efficacy and safety outcomes of the Phase 3 DAYLIGHT Study
Presentation Date and Time: October 13, 2023; 8:52 AM ET
Presenter: Brandon Busbee, M.D., Tennessee Retina and Retina Consultants of America
View Presentation
Title: Tarcocimab tedromer (KSI-301) Anti-VEGF Antibody Biopolymer Conjugate for Diabetic Macular Edema: Primary Endpoint Efficacy and Safety Outcomes of the GLEAM and GLIMMER Phase 3 Pivotal Studies
Presentation Date and Time: October 13, 2023; 10:28 AM ET
Presenter: Robert Wong, M.D., FASRS, Austin Retina Associates
Title: Tarcocimab tedromer (KSI-301) 5 mg for the treatment of RVO: One-year primary efficacy, durability, and safety outcomes of the Phase 3 BEACON Study
Presentation Date and Time: October 13, 2023; 10:38 AM ET
Presenter: Ankoor Shah, M.D., Retina Consultants of Texas
Presenter: Dr. Charles C. Wykoff, MD, PhD
Presenter: Michael A Singer, M.D., Clinical Professor of Ophthalmology, University of Texas Health Science Center, and Director of Clinical Research, Medical Center Ophthalmology Associates, San Antonio, TX
Presenter: Arshad Khanani, M.D., M.A., FASRS, Director of Clinical Research, Sierra Eye Associates, Reno, NV
Presenter: Carl Regillo, M.D., Chief of Retina Service, Wills Eye Hospital / Thomas Jefferson University, Philadelphia, PA
Presenter: Carl Regillo, M.D., Chief of Retina Service, Wills Eye Hospital / Thomas Jefferson University, Philadelphia, PA
February 13, 2021
8:30 AM ET
Presentation by Diana V. Do, MD
KSI-301: Intravitreal Antibody Biopolymer Conjugate that Demonstrates Extended Durability in Wet AMD and Retinal Vascular Diseases
Late Breaking Developments, Part II
Presentation by Arshad Khanani, MD
One Year and Beyond: Long-Term Multiple-Dose Study of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate with Extended Durability, in wAMD, DME, and RVO
Session 1.1: Age-related Macular Degeneration: A Focus on Durability
Presentation by Arshad Khanani, MD
Updated Results of Phase 1b Study of KSI-301, an Anti-VEGF Antibody Biopolymer Conjugate w Durability, in wAMD, DME, and RVO
*Data presentation same as July 10 data
Sunday, July 26, 2020
11:10am EDT
Presentation by Mark Barakat, MD
One-Year and Beyond: Results of Phase 1b Study of KSI-301, an AntiVEGF Antibody Biopolymer Conjugate With Extended Durability, in wAMD, DME, and RVO
Presentation by Diana V. Do, MD
Update on Phase 1b and Phase 2 Studies of KSI-301: A Novel Anti-VEGF Antibody Biopolymer Conjugate with Potential for Extended Durability in Wet AMD
Kodiak management will provide regulatory updates on the company’s “2022 Vision” for KSI-301 following from a successful FDA end-of-phase 2 meeting held on October 30, 2019, and discuss new data from its on-going Phase 1b clinical study of KSI-301 as well as other business highlights for the third quarter ended September 30, 2019.
Retina Subspecialty Day: October 11-12, 2019
Friday, October 11, 2019
4:58pm PDT
Presentation by Charles C. Wykoff, MD, PhD
Extended Durability in Exudative Retinal Diseases Using the Novel Intravitreal Anti-VEGF Antibody Biopolymer Conjugate KSI-301: Results From the Phase 1b Study in Patients with wAMD, DME and RVO
Sunday, September 15, 2019
11:08am BST
Presentation by David Brown, MD
Novel Anti-VEGF Antibody Biopolymer Conjugate KSI-301 with Potential for Extended Durability in Retinal Vascular Diseases: Late-Breaking Results from a Phase 1b Study in Patients with wAMD, DME and RVO
Thursday, September 5, 2019
11:59am CEST
Presentation by Pravin U. Dugel, MD
Session: Novelties and Late Breaking Developments in Retina & Technology
Title: Novel anti-VEGF antibody biopolymer conjugate KSI-301 with potential for extended durability in retinal vascular diseases: first-time results from a phase 1b study in patients with wAMD, DME and RVO
Sunday, September 8, 2019
9:48am CEST
Presentation by Pravin U. Dugel, MD
Free Paper Session
Title: Extended durability in exudative retinal diseases using a new class of molecules: novel anti-VEGF antibody biopolymer conjugate KSI-301: first-time results of the phase 1b study in patients with wAMD, DME and RVO
Saturday, July 27, 2019
11:48am CDT
Presentation by Pravin U. Dugel, MD
Antibody Biopolymer Conjugates: A Novel Scientific Approach and Platform for Extended-Durability Retinal Medicines - First Results from a Phase 1b Proof of Concept Study of KSI-301, an anti-VEGF ABC
Presentation by Diana V. Do, MD
KSI-301: Update on Phase 1 Studies with a First in Class Antibody-Biopolymer Conjugate for Treatment of Wet AMD, DME, and Other Retinal Vascular Diseases